Kite Pharma Reports That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma